FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3156211200> ?p ?o ?g. }

• W3156211200 endingPage "3540" @default.
• W3156211200 startingPage "3540" @default.
• W3156211200 abstract "There is little evidence on the use of sodium−glucose cotransporter 2 inhibitors in hospitalised patients. This work aims to analyse the glycaemic and clinical efficacy and safety of empagliflozin continuation in patients with type 2 diabetes hospitalised for acute decompensated heart failure. This real-world observational study includes patients treated using our in-hospital antihyperglycaemic regimens (basal-bolus insulin vs. empagliflozin-basal insulin) between 2017 and 2020. A propensity matching analysis was used to match a patient on one regimen with a patient on the other regimen. Our primary endpoints were the differences in glycaemic control, as measured via mean daily blood glucose levels, and differences in the visual analogue scale dyspnoea score, NT-proBNP levels, diuretic response, and cumulative urine output. Safety endpoints were also analysed. After a propensity matching analysis, 91 patients were included in each group. There were no differences in mean blood glucose levels (152.1 ± 17.8 vs. 155.2 ± 19.7 mg/dL, p = 0.289). At discharge, NT-proBNP levels were lower and cumulative urine output greater in the empagliflozin group versus the basal-bolus insulin group (1652 ± 501 vs. 2101 ± 522 pg/mL, p = 0.032 and 16,100 ± 1510 vs. 13,900 ± 1220 mL, p = 0.037, respectively). Patients who continued empagliflozin had a lower total number of hypoglycaemic episodes (36 vs. 64, p < 0.001). No differences were observed in adverse events, length of hospital stay, or in-hospital deaths. For patients with acute heart failure, an in-hospital antihyperglycaemic regimen that includes continuation of empagliflozin achieved effective glycaemic control, lower NT-proBNP, and greater urine output. It was also safer, as it reduced hypoglycaemic episodes without increasing other safety endpoints." @default.
• W3156211200 created "2021-04-26" @default.
• W3156211200 creator A5001166035 @default.
• W3156211200 creator A5018145028 @default.
• W3156211200 creator A5019296994 @default.
• W3156211200 creator A5036360770 @default.
• W3156211200 creator A5040021987 @default.
• W3156211200 creator A5051174812 @default.
• W3156211200 creator A5055202156 @default.
• W3156211200 creator A5067333354 @default.
• W3156211200 creator A5075798528 @default.
• W3156211200 creator A5082245964 @default.
• W3156211200 creator A5083176303 @default.
• W3156211200 creator A5087465273 @default.
• W3156211200 date "2021-08-12" @default.
• W3156211200 modified "2023-09-29" @default.
• W3156211200 title "Efficacy and Safety of Empagliflozin Continuation in Patients with Type 2 Diabetes Hospitalised for Acute Decompensated Heart Failure" @default.
• W3156211200 cites W1979974003 @default.
• W3156211200 cites W2018247534 @default.
• W3156211200 cites W2099853060 @default.
• W3156211200 cites W2106327047 @default.
• W3156211200 cites W2146264128 @default.
• W3156211200 cites W2153098857 @default.
• W3156211200 cites W2335312575 @default.
• W3156211200 cites W2427094903 @default.
• W3156211200 cites W2560368270 @default.
• W3156211200 cites W2599515436 @default.
• W3156211200 cites W2606853863 @default.
• W3156211200 cites W2626446274 @default.
• W3156211200 cites W2885635359 @default.
• W3156211200 cites W2891794449 @default.
• W3156211200 cites W2900413769 @default.
• W3156211200 cites W2901813837 @default.
• W3156211200 cites W2939222610 @default.
• W3156211200 cites W2943662632 @default.
• W3156211200 cites W2969766757 @default.
• W3156211200 cites W2974260792 @default.
• W3156211200 cites W3000647500 @default.
• W3156211200 cites W3014388459 @default.
• W3156211200 cites W3018034579 @default.
• W3156211200 cites W3089283105 @default.
• W3156211200 cites W3100542962 @default.
• W3156211200 cites W3134275835 @default.
• W3156211200 cites W3155840904 @default.
• W3156211200 cites W3156112919 @default.
• W3156211200 cites W4236126199 @default.
• W3156211200 cites W4248302664 @default.
• W3156211200 cites W4293860347 @default.
• W3156211200 doi "https://doi.org/10.3390/jcm10163540" @default.
• W3156211200 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8396978" @default.
• W3156211200 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34441835" @default.
• W3156211200 hasPublicationYear "2021" @default.
• W3156211200 type Work @default.
• W3156211200 sameAs 3156211200 @default.
• W3156211200 citedByCount "5" @default.
• W3156211200 countsByYear W31562112002021 @default.
• W3156211200 countsByYear W31562112002022 @default.
• W3156211200 crossrefType "journal-article" @default.
• W3156211200 hasAuthorship W3156211200A5001166035 @default.
• W3156211200 hasAuthorship W3156211200A5018145028 @default.
• W3156211200 hasAuthorship W3156211200A5019296994 @default.
• W3156211200 hasAuthorship W3156211200A5036360770 @default.
• W3156211200 hasAuthorship W3156211200A5040021987 @default.
• W3156211200 hasAuthorship W3156211200A5051174812 @default.
• W3156211200 hasAuthorship W3156211200A5055202156 @default.
• W3156211200 hasAuthorship W3156211200A5067333354 @default.
• W3156211200 hasAuthorship W3156211200A5075798528 @default.
• W3156211200 hasAuthorship W3156211200A5082245964 @default.
• W3156211200 hasAuthorship W3156211200A5083176303 @default.
• W3156211200 hasAuthorship W3156211200A5087465273 @default.
• W3156211200 hasBestOaLocation W31562112001 @default.
• W3156211200 hasConcept C126322002 @default.
• W3156211200 hasConcept C134018914 @default.
• W3156211200 hasConcept C164705383 @default.
• W3156211200 hasConcept C17923572 @default.
• W3156211200 hasConcept C2775887513 @default.
• W3156211200 hasConcept C2777180221 @default.
• W3156211200 hasConcept C2778024521 @default.
• W3156211200 hasConcept C2778198053 @default.
• W3156211200 hasConcept C2779295919 @default.
• W3156211200 hasConcept C2779306644 @default.
• W3156211200 hasConcept C2780473172 @default.
• W3156211200 hasConcept C2781413609 @default.
• W3156211200 hasConcept C555293320 @default.
• W3156211200 hasConcept C71924100 @default.
• W3156211200 hasConceptScore W3156211200C126322002 @default.
• W3156211200 hasConceptScore W3156211200C134018914 @default.
• W3156211200 hasConceptScore W3156211200C164705383 @default.
• W3156211200 hasConceptScore W3156211200C17923572 @default.
• W3156211200 hasConceptScore W3156211200C2775887513 @default.
• W3156211200 hasConceptScore W3156211200C2777180221 @default.
• W3156211200 hasConceptScore W3156211200C2778024521 @default.
• W3156211200 hasConceptScore W3156211200C2778198053 @default.
• W3156211200 hasConceptScore W3156211200C2779295919 @default.
• W3156211200 hasConceptScore W3156211200C2779306644 @default.
• W3156211200 hasConceptScore W3156211200C2780473172 @default.
• W3156211200 hasConceptScore W3156211200C2781413609 @default.
• W3156211200 hasConceptScore W3156211200C555293320 @default.

• next